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Abstract
For Lhe greater Lhan one million Americans who rely on supplemental oxygen
for survival , Lhe vast majority of them struggle wilh ambulatory oxygen sources which
restrict their abiUty to move freely about wilbin and out of their homes. Liquid ox)gen
sources can provide the smallest and longest lasting ambulatory oxygen supply.
However, the cost of the provision on liquid oxygen has historically been cost prohibitive
under our current Medicare reimbursement schedule. The HELiOS™ Oxygen System by
Puritan-Bennett a division of Mallinckrodt. has developed an oxygen system, which
allows for the smallest, lightest weight and longest lasting oxygen system ever developed.
This system was a]so designed with special considerations for reducing the cost of
provisi.on and therefore, more acceptable in today's restraints on Medicare
reimbursement.
This study was designed to examine the potential issue of U1e HELiOS product
to effectively oxygenate patients during hours of sleep. In addition, i.l wi ll discuss the
philosophical issues of compliance with oxygen therapy orders when oxygen sources are
provided which significantly reduce quality of life issues for the patient. This research
showed Urnt of a small sample of 19 subjects, 63% ( 12 subjects) ex perienccd saturations
that were not clinicaJJy significantly different from Lhat which they experienced on their
current continuous oxygen flow source. Collective data in a two-tailed t-test resulted in a
p value of= 0.00 I, indicating that there is a statistically significant, high probability that
the saturation of a randomly chosen oxygen therapy patient· s oxyge1J saturation would
not be clinical cquaJ to tbat of the same patient on continuous now oxygen. Therefore,
this researcher would recommend an overnight oximetry be performed for most all
patients who wi ll be converting from continuous tlow oxygen to the HELiOSTM Demand
Flow Oxygen System <luring hours of sleep.
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Chapter I

INTRODUCTION
Home oxygen delivery

T here are approxi mately 1.2 million patie nts in the United Slates receiving
oxygen therapy. The primary diagnosis requiring treatment with oxygen therapy is
Chronic Obstructive Lung Disease (COPD). This disease classifica tion includes
patients suffering from Emphysema, Chronic Bronchitis, Bronchiectasis, and
Asthma. It is estimated that approximately 200,000 new patients will require
oxygen therapy in the United States alone in Lhe year 2000 (Frost, 1999). With the
great number of patients receiving and expected to begin receiving oxygen therapy,

one would thjnk that this would be an area of great research and development
interest to not only physicians but also medical device manufacturers. However,
quite the o pposite is true. There have been very few comprehensive, definitive
stucLies o n the topic. The most recent comprehensive studies were published in
1980 and 198 1 (NOTT 1980, MRCJ98 1). There have also been very few
breakthrough products develo ped for the delivery of oxygen therapy in the past 20
years. The products that have been developed do not have a comprehensive
scope. These products are primarily comprised of oxygen concentrators,
conventional Liquid oxygen systems, and oxygen conserving devices to be used
with compressed gas tanks (O' Donohue 1997). These products may assist the
oxygen provider company by reducing the cost and may slightly improve
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portability of the ambulatory oxygen, but they do a very poor job in addressing the
issues of all of lhe stakeholders in the oxygen supply process, including the patient,
physic ian, provider, payer and producer. It is essential that more in -depth research
in this area takes place and that manufactures (producers) of
medical equipment begin looking for products that meet the requirements of all
stakeholders in this process.

In an attempt to create a revolutionary oxygen product that considers the
interesl of each of the previously mentio ned shareholders in the provisio n of
oxygen, Puritan-Bennett has developed a home oxygen delivery device that has the
potentiaJ to do just that. However, this device as cu1Tently designed (PB, 1999) is
not without its own set of challenges. This device, for optimum economic
efficacy, relies o n the use of an oxygen-conserving device to be used on a 24-hour
per day basis. Prio r to the development of this product there had been few
attempts to develop a conserving device to be used during hours of sleep
(Cuvelier,1999, Bower, 1988). Those altempts that had been made were either
relatively unsuccessfu l or required a design element whicb would significantly
increase the price of the provision of the device, therefore removing it as a feasible
opti.on under the current economic restrain ts of the third party payer systems,
especially Medicare. Secondly, none of the previously attempted designs provided
fo r a mechanism, which would encourage patients to use their oxygen more ho urs
of the day.

3

The question to be explored in the study of this new device wiJJ be; Will
this device allow for adequate oxygenation of COPD patients during hours of
sleep? Thi<; study was designed to examine this ques tion in regards to subjects
who have ctment prescriptions for long tenn oxygen lherapy for supplemental use
and would fall into the criteria of supply of low flow oxygen as provided by lhe
study device. ft is hypothesized that thi s device will be effective in oxygenation of
70% of subjects equal to that of continuo us flow oxygen and that no subjects will
reach an oxygen saturation level that would require intervention.
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Chapter II
LITERATURE REVIEW
It has been shown that the use of oxygen therapy can inc rease survival
rates fo r patients with chro nic lung disease. The benefit of long-term oxyge n
therapy was undisputedly proven in the studies of the Medical Research Council of
the U nited Kingdom (MRC, 198 I ) and the Nocturnal Oxygen Therapy Trials

(NOTI, 1980) pedormed in the United States. The MRC study, which compared
several outcome measures of 87 c hronically hypoxemic patients suffering from
lung disease, observed patients over a minimum of two years. Patients wbo were

equally matched in severity and disease process were divided into two groups.
The control group would not receive any oxygen the rapy except in acute
exacerbation requiring hospitalization. The study group would receive oxygen
during the evening and night hours with a mean use time of 15 hours per day. This
study showed that subjects in the study group, receiving oxygen therapy for
approximately 15 hours pe r day, had much improved clinical outcomes including
an improved survival rate at 24 months of 62% verses the control group with
survival rate of o nly 50% (MRC, 1981).
Conc urrent wilh the findings of the MRC study, a similar study was taking
place in the United Stales observing the effects of oxygen therapy on a group of
203 subjects. This study looked at a control group of patients who received
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oxygen therapy for approximately 12 hours per day or while sleeping. An equally
matched group making up the study group was asked to use their oxygen therapy
o n a continuous basis. These subjects were provided with portable oxygen
equipment that at the time of the study was state of the art and included portable
8-pou nd liquid oxygen units. The results of this study were si milar to the MRC
study in that the subjects who used their oxygen therapy more hours per day had
much-improved outcomes. The two-year survival of the nocturnal oxygen therapy
users was approximately 58% while that of the continuous oxygen therapy group
was approximately 78% (NOTT, 1980).
Upon a closer look at the reported data from the NOTT trial, it sho uld be
noted that the subjects who were asked to use their oxygen therapy nocturnally
were very successful in doing so, with a mean duration of oxygen therapy 12 hours
per day. Subsequently, the subjects who were asked to use their oxygen therapy
on a continuo us basis were not qui te as compliant with the request of the
investigators. T he mean duration of use for these subjects was 19.3 J1o urs per day.
The reason for non-co mpliance was not recorded as an outcome measure of this
study (NOTI, J980). However, upon interview of one of the primary
investigators of this study, Dr. Thomas Petty, three primary reasons for non complia nce were recalled in this group. The first reason was that the continuous
flow of oxygen had a significant drying effect o n the nares of the patients. These
patients intermittently removed their oxygen to allow for rest periods to rehydrate
the nasaJ mucosa. The second reason recalled was that the subjec ts' ears would
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become sore from the p ulling of the SO-foot nasal cannula used i n Lhe home. The
subjects would re mo ve the oxygen therapy lo aUow fo r rest periods of the skin
around the ears and to be free for a period of t ime from the nuisance o f the
restricting tubing length. T he third rea<.;on reported was that the patients did not
always use their oxygen therapy when leaving the ho me . Two major contributors
to this non-compliance issue could be the sel f conciseness of the patients of the use

of oxygen due to the appearance of the oxygen equipment, and the effort required
to switch to the portable source and the cumbersome equipment □eeded to do so

(Petty, 1999). These findings perplex and concern many clinicians that seek ways
to improve compliance and thus improve o utcomes of their oxygen therapy
patients.

With a mathematical exn·apolation it can be estimated that the survival
percentage of subjects who were to use their oxygen therapy for up lo a 23 hour
per day basis would be even more significantly improved than that of the
continuo us oxygen therapy sub-set of patients observed in the NOTT study. An
example of this extrapolation can be seen along with the actual data points of the
NOTT and MRC data point sets, in Fig ure L. This chart makes a compelling
argument that the medical community must find ways to overcome the current
objections to oxygen therapy use on a 24-bour basis in order to improve survival
outcomes for this group of patients.
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Puritan- Bennett, a subsidiary of Mallinckrodt, Lnc . has devised a product
to address the primary, known obj ections of patients to the 24-hour per day use of
oxygen therapy. This p roduct is named HELiOSTM , which is an acronym for
' •High Efficiency Liq ujd Oxygen System". This system combi11es the use of a
very small cryogenic container of oxygen with a pneumatic oxygen-conserving
device to al low the patient interface to be a very sma ll, lightweight unit of only
3.4 pounds when full. Trus unit will last for up to IO hours for the 2-liter per
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patient. The system is designed to allow the user to fill the portable unit in the
morning and place it into a waist pack, chest s trap, or back pack, for up to ten
ho urs o f "hands free" oxygen use. Sometime throughout the day the patient would
need to "lop o lf ' the unit to allow them to move freely inside aad o utside o f the
home for the remainder of their hours of mobility. When settling in for the night
the patient, continuing Lo use the same interface, would simply attach connecting
tubing up to 100 feel long, from the s tationary unit to the portable unit. This
wou ld allow the patient to firs t utilize any remaining oxygen in the portable
therefore, not wasting the o xygen remaining in the bottle. When the portable
becomes empty during the night, the evaporative gas of the liquid s tationary that
has been storing all day for njghttime use wo uld then supply the oxygen.

This system design effectively deals with all of the reported objections to
the 24-hour compliance issue seen in the NOTT study. The oxygen tlow is not
continuous at any liter flow greater than o ne liter per minute of flow. It is only
provided during inspiration. This demand oxygen system reduces the drying effect
of the nasal mucosa seen with continuous oxygen therapy while continuing to be
very effective in oxygenating patients. The ability of patients to utilize the Lightweight "hands free" system even while in the ho me, eliminates the need for the
patient to be te thered to a 50 foo t tubing which conventionally provides oxygen
therapy for patients in their homes from a stationary source. This elimination of
the 50-foot supply tubing for use in the ho me sig nificantly reduces the pulling of
the cannula on the patients' ears, reducing the skin irritation seen wi th
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conventional systems. Additional benefits for this i_nclude improved freedom from
the statio nary unit and tbe elimination of need to change the interface when one
wishes to move beyond the 50-foot radius from the stationary. The removal of the
need for the supply line also reduces the fall hazard

LO

the patient and others in the

home due to the removal of the supply tubing througho ut the home. Finally, this
state of the art system provides a very small, sleek oxygen interface that has a nonmedical appearance (See figure 2). The ease of use should contribute to improved
compliance.
The Helios TM unit incorporates a patented des ign for the oxygen
container. Historically, cryogenic (liquid oxygen) vessels were designed like a
bottle. These standard bottles have a neck at the to p of the bottle where the

evaporation to a gaseous form of the oxygen takes place. This old design requires
that the bo ttle be kept up right in o rder for the liquid oxygen lo remain in proper
position in the bottom of the bottle. If the bottle were to Lip over on its side, the
oxygen container will begin to hiss and vent the oxygen. Within a few minutes the
liquid oxygen could actually spiU from the containe r, creating a cold burn hazard to
the patient sho uld they touch this material that is at a temperature of approximate.ly
minus 300 degrees Fahrenheit (PB, 1987). The new HELiOS TM container design
is built like a tanker truck or a closed soda can. This closed design incorporates a

floating tube, which is used to pull up the liquid oxygen into the warming coils for
evaporation into the gaseous slate. This design allows rbe container to have
excellent tip over characteristics. The vessel is designed to operate in the upright
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operate i□ the upright and horizontal positions. This design is not only beneficial
from a safety stand point, but a lso allows for the most convenient transport of the
unit i_n. many configurations, there in reducing the anxiety of Lbe patient during
outiJ1gs from the home (PB, 2000).

Figure 2

(Phologniph councsy ol' Molhnckrod1, lnc.-ruman-Bennell product linc-S1.l..uuis. M01

The use of smal1ru1d very portable oxygen systems, which allow for ease in
ambulation for patients, has many benefits iJ1 addition to improved compliance.
The pos itive effects of pulmonary rehabilitation programs with the use of
ambulatory oxygen systems have been well documented (Clark 1996, Harris 1996,
Dean 1992, Criner 1987). A study by Janssens et.al. published in 1997 showed a
direct correlation between distance walked per day with the quality of life score of
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patients with chronic pulmo nary d isease (Janssens, 1997). A second study
published in 199 1 by Lock et.al. co mpared lhe number of ho urs of ambulation
outside of Lhe home for patients who were utilizing liqu id oxygen portables
weighing approx._imately 8 lbs. and lasting for abo ut 4 ho urs Lo patient who used E tank sized cyli nders of compressed gaseous oxygen in carts weighing
approximately 15 pounds and las ting approximately 5 ho urs. The results of this
study showed that Lbose patients who were provided with the liquid oxygen
systems ambulated a mean of 23.5 ho urs per week while the matched group using
the gaseous oxygen source o nly ambulated a mean of IO hours per week (Lock,

1991).
T he overwhelming benefit of the use of liquid o xygen therapy systems begs
the question, "Why are all oxygen therapy patients who have the ability and desire
to ambulate no t provided liq uid oxygen systems?" The answer to this question is
that there are many other stakeho lders involved in the provis ion of oxygen therapy
in the United States. Both the Ho me Care Company providing the oxygen therapy
modality and the third party payer who contributes to the reimbursement for this
therapy are sig nificant co nt ributors to the detennination of the modality of oxygen
provided to patients. Because the majority of oxygen therapy patients are
Medicare beneficiaries, the reimbursement by Medicare as the third pa11y payer to
lhe Home Care Co mpany for the provision of the oxygen therapy significantly
impacts the type of oxygen provided. The reimbursement of oxygen Lherapy to the
Ho me Care Co mpany by Med icare is " Modality Neutral" ( Petty, 1990). T his
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means that the Horne Care Company is reimbursed the same amount by Medicare
fo r the provisio n of the oxygen therapy equipmenl, supplies, and service, with no
differentiation for mo re ambulatory oxygen so urces. Compounding this problem is
the fact that the reimburseme nt for oxygen therapy to Ho me Care Companies by
Medicare was red uced by 25% in 1998 and was reduced by an addjlio nal 5% in

1999. This was a direct effect of the Balanced Budget Act of 1998. Because
conventio nal liquid oxygen sources requ ire the Home Care Company to send
someone o ut to the home approximately o nce per week to refill the stationary
oxygen vessel, the cost of providing the "service" requi red with conventional liquid
oxygen systems bas been cost prohibitive. Oxygen concentrators, requiring o nly
o nce every three month visits for mamtenance are much less expense to provide
(PB, 1999). However, oxygen concentrators do n6l provide for an ambulatory
source o f oxygen for patients.
In an attempt to reduce the cost of lo ng-tenn oxygen therapy, (LTOT),
conserving devices have been developed which deliver oxygen at the point during
inspiratio n, whlch is most effective for oxygenation. To Lhis po.int most oxygen
conserving devices have been used to conserve oxygen in portable oxygen systems.
This has become a ve1y popular way of providing ambulatory oxygen with a
compressed gas tank called and M-6 and can be used in conjunction w.ith an
oxygen concentrator to be used while the patient is at home. This system typically
allows a 5.5-6 pound system to last for anywhere from 4-6 ho urs fo r the typical 2liter per mfoute patient. Altho ugh thjs has been found effective in reducing the
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cost of Lhe provision o f ambula to ry oxygen (Stiegmeyer, 1999), this system is not
without many drawbacks. Many of these conserving devices used with
compressed gas cylinders are very compl icated and require significant dexterity by
the patient to rem ove the regulator, open the tank, and remember the sequence in
order to initiate the functio n of the conserving device.
As previously mentioned, the stationary system used with this modality is
typically ao oxygen concentrator. This is a machine that is powered by electric ity.
It draws in air from the room. Air is comprised of approximately 21% oxygen,

78% nitrogen, and 1% various o ther trace gasses. The oxygen concentrator then
filters the air through cylinders filled with a molecular sieve, which removes the
nitrogen fro m the air. The remaining oxygen and o ther trace gases are then

compressed and emitted from the oxygen concentrator with tlow rates that vary
from typically½ to 5 liters per minute with an oxygen purity of approximately 9294% pure oxygen (Scanlan, 199). Although this system is very economical for the
Home Care Company to provide, it has several negative implications for many
patients. First, the concentrator operates from an electrical source. Depending
upo n the regio n and electrical prices in the area, the use of a concentrator may
increase the elect1ical bill of the patient from $240 to $300 per year (Petty 1994).
There is litlle to no government assistance or reimbursement for this additional.
cost.

The concentrator also makes noise, which is unacceptable to many patient<;.

An example of the concentralor and compressed gas cylinders can be seen in
Figure 3. The use of the concentrator in the home and d1e small compressed gas
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compressed gas cyl inders for activity outside the home does not address the need
to be tethered to the concentrator by a 50 foot extens ion tubing while the patient is
in their home. It also adds a level of complexity to the desire of the patient to
leave their home. Because the patient must di scontinue the use of the oxygen
concentrator and injtiate the use ofthe compressed gas w ith conserving device
source, tbe patient may detennine that the effort required to leave the home while
utilizing the oxygen therapy is s imply not worth the effort (Oji le, 1999). T hey
will then either leave the home without the use of their oxygen or worse, not leave
home at al l.

Figure 3

(Photograph Courtesy of Mallinckrodt, lnc.-Puritan Bennett product linc-S1.Charles, Mo)
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The HELiOSTM oxygen system effectively deals with many of the barriers
of oxygen therapy provisio n. In addition to the many patient benefits that it
provides, its patented designed storage system aUows it Lo be as eco no rnical as the
concentrator and small cylinder optio n for any arnbuJatory patient whose c urrent or
desired life-style would req uire at least monthly delivery of smal I tanks for use
during ambulatio n.
The overalJ economic benefit of the HELiOSTM system is most prudent if
the system can be used by the patient breathing through the portable unit on a 24hour basis. This creates a sig nificant challenge for this product. To this point,
oxygen-conserving devices have primarily been used by patients during ambulatio n
o nly. The use of various types of conserving devices has been shown to be

effective in the oxygenation of the ambulatory patient i_n several studies (Carter,
1989,Rinow 1986, Braun 1992, Mecikalski, 1984, Stegmaier, 1999). However, a
limited number of attempts have been made to utilize oxygen-conserving devices
during sleep and have for the most part been unsuccessful in doing so.
The bases of this empirical research wi ll be the attempt to determine the
significance to patient outcomes in the use of the HELiOS™ oxygen therapy
product o n a 24-hour per day basis. The focus of the research will be to determine
the implicatio ns of the use of this pneumatic oxygen-conserving device d uring
sleep. In order Lo promote use or these devices o n a 24-bo ur basis, it is first
necessary to understand their effectiveness in the oxygenation of patients and
specificaJJy patients during sleep.
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T his study wiJ I compare the efficacy of a pneumatic demand device (PDD)
to a standard continuo us flow system in maintaining oxygenation of s ubjects with
chro nic lung disease requiring oxygen therapy during sleep. ln a previous trial
using a similar Mallinckrodt device, oxygenation was substantially equivalent in
70% of subjects utilizing a similar PDD during sleep when compared wilh
continuous flow oxygen (Sa02 ± 2%). Subjects who failed to meet the success
criterion of no episodes of> five consecutive minutes of oxygen desaturation to
less Lhaa 90%, were attributed to failure to trigger the device.
In this study, s ubjects we re observed in the sleep lab under full polysomnography
for a total of three nights. The first night served as an acclimation night as well as
a nig ht to titrate the patient's oxygen to determine actual nocturnal oxygen needs.
This acclimation night was also used as a nig ht for screening any patients who
suffered from obstructive sleep apnea. The patieats were then randomized to
either continuous flow oxygen or oxygen via the demand conserving device.
O utcome measures from this sLUdy .included the quality of sleep while utilizing
each mode of oxygen therapy. The qual.ity of sleep was quantified in number of
minutes spent in REM as well as the number of arousal throughout the entire sleep
period. This o utcome measure was of interest to deterrnine if the intermittent
"puffs" of oxygen o r the no ise created by the device would arouse patients from
sleep o r cause them to have a lower quality to sleep.
The second o utcome measure to be determined was if the volume o f
oxygen delivered by the conserving device was adequate to maintain oxygen
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satmation equaJ to that of continuous flow. Any variance greater than 2%
saturation points fro m the mean and lasting for greater than five minutes would be
considered a significant decrease in saturation. T hese episodes of desaturation
would of course onJy be considered t:o be due to lack of volwne of oxygen
delivered if they occurred when the patient was consistenlly triggering the oxygenconserving device. The third outcome measure was to detennine if Lhe patients
could maintain saturation equaJ to continuous flow even .in a s ituatio n of "failure to
trjgger" the device. This is o f importance because it was hypothesized that the
target population fo r this product, Chronic Obstructive Pulmo nary Disease
(COPD) patients would experience at least some failure to trigger of the device
over the entire sleep period despite its extreme sensitivity . Both the

pathophysiology or the COPD patient and previously documented attempts at the
use of oxygen conserving devices during sleep would suggest that this might occur
(Cuvelier, 1999, Kacmarek, 1990).
COPD patients suffer from a condition that causes air to be trapped within
the lungs.

This air tra pping results ia the eventual expansion of the diameter of

the ches t wall and therefore, loss of the naturaJ, elastic recoil of the chest during
the expiratory phase of breathing. T his further exacerbates the problem of the air
trapping. This increased air trapping begins to press downward 0 11 the
diaphrag matic musc le. HeaJLhy people rely

0 11

the contraction of the diaphragms

to drop enough to create a vacuum, which results in a negative pressure to be
created. Thls causes a ir to flow into the lungs. H owever, due to the fact the
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d iaphragms o f a COPD patient are flattened from the air u·apping, it becomes
difficult for the contraction of the diaphragms alone to create enougb negative
pressure to create an appropiiatc level of ai rflow. To compensate for the deficit,
COPD palieDts use what is known as the accessory muscles of respiration to assist
in the movement of the chest wall great enough to create a significant negative
pressure. The healtby person when over exerted uses these skeletal muscles of the
neck, chest wafl, and abdomen and a need has been created to brealh much more
deeply than no rmal. T he need fo r COPD patients to use their accessory muscles of
respiratio n to create a negative pressure becomes problematic during sleep in the
attempt Lo trigger a demand system of oxygen fl ow. During deep s leep known as
Stage IV and more significantly in REM (R apid Eye Movement) s leep, the skeletal

muscles of the body are in a paralytic state. This tolal lack of movement of the
skeletal muscle o f the body is w hat causes one to feel rested in the morning. This
is why the quality of an individual's sleep is often quantified in the time spent in
REM. Altho ugh the demand oxygen-conserving device being studied needs only a
very little negative pressure in order to trigger (0 .05 cm H 2 0 ), even this minuet
amount of pressure may not be created during REM s leep in the COPD patient.
This s tudy is being conducted to expl ore increased sensitivity for triggering
and to provide o ptio ns fo r subjects who cannot trigger the device. To date, most
slud ies bave shown thal oxygenation of subjects with conserving devices is mos t
effective when the majority of 1l1e oxygen provided is supplied during the fi rst 0.3
seconds of inspiratio n (Bliss, 2000). Such devices have been proveu effective
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dw-ing wakefu l bo urs (at rest and exerc ise) and similar data reproduced in vario us
studies(Braun, 1992, Tiep, 1995). With previo usly produced and marketed
conserving devices, patients were only encouraged to use the device during
ambulatio n outside of the home. However, the HELiOSTM producl is designed for
use o n a continuous basis. This product design is requiring that patients use a
conser ving device during all activities of daily living, including exercise, rest and
sleep. Chapter III of this manuscript will provide the research protocol and design
established to evaluate the efficacy of the HELiOSTM oxygen conserving system.
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Chapter Ill
Methodo logy

Study RalionaJ
This study was designed to examine the efficacy of a Pneumatic Demand
Device (PDD) in the oxygenation of subjects with chronic lung disease
requiring oxygen therapy d uring sleep. Previous medical trials have shown
that 70% of subjects utilizing a similar PDD during sleep oxygenated as
weU (Sa02± 2%) as they did while using continuous flow oxygen
(MaUfockrodt , 1999). Subjects who fail ed to meet the success criteria
defined as no episodes of> five consecutive minutes of desaturation of <
90%, could be attributed to fai lure to t1i gger the device. This study was
conducted to explore the possibilities of increasing sensitivity and to
provide options for subjects who cannot trigger the device. ft has been
shown that the use of oxygen du ring sleep can increase survival rates for
subjects with chronic lung disease (MRC, 198 1, NOTT. 1980). In
attempts to decrease health care spending, devices have been developed to
conserve oxygen by delivering the oxygen a l the point d uring inspiration
that can most efficiently be utilized fo r oxygenation. If such devices could
be proven to be effective i11 tbe oxygenation of sleeping patie nts, their use
on a 24bour per day basis wou ld dramatically reduce the cost of providing
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L ong Term Oxygen T herapy. To dale the majo rity of studies have sbown
that oxygenatio n of subjects with conserving devices are most e ffective
when the majority of the oxygen provided is supplied during the first 0.3
seconds of inspiration (Bower, 1988). Such devices have been proven
effective during wakefuJ hours (at rest and exercise) and replicated in
various studies ( Braun, 1992, NPB, 1998).
This study was designed to look at the ability of a POD lo provide
oxygenation equaJ to that of continuous flow during sleep. lt is known that
the level of oxygenation is altered during sleep. This is thought to be most
likely fro m the recumbent position during sleep decreasing the level of
movement in Lhe djaphragrn and therefore decreasing the lotaJ amount of
airflow into the lu11gs. This problem is exacerbated in the COPD patient
due to diaphragmatic fatigue and hyperinflation (Scanlan, 1999). Further
concerns have been raised by Lhe display of altered chest wall and muscle
excursion during REM sleep in healthy subjects (Becker, 1999). Patients
suffering from COPD must utilize accessory muscles for adequate
ventilation and thus oxygenation. This makes the sensitivity of conserving
devices utilized during sleep key in the efficacy of the uni t.
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Study Ob1ect\ves
The objectives of this sleep study were as follows:
I. To evaluate the ability of a 4: 1 pneumatic conserving device to provide
equivalent oxygenation of patients as wi_th continuous flow oxygen during
sleep.
2. To evaluate the quality or sleep of patients using an oxygen-conserving
device compared with their quality of sleep during use of continuous flow
oxygen.
3 . To compare the performance of a variable flow-conserving device with
previously studied POD and continuous flow oxygen in the oxygenation of

patients during sleep.
Methods
A total of 20 subjects currently utilizing supplemental oxygen were
recruited for this study. Patients underwent a pulmonary func tion test
including spirometry, plethysmography, and diffusion measurement to
characterize the severity of their COPD. S ubjects underwent either 3 or 4
nights of polysomnography recording on consecutive nights.
Polysomnography wm; performed in the sleep lab. The first night served as
an acclimation njght (Toussaint, 1995). This first night also served as an
evaluation for exclusion of subjects with Obstructive or Central Apnea,
defined as greater than ten apneas or hypopneas per ho ur of sleep. During
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the acclimation night subjects breathed oxygen per nasal cannula al their
previously prescribed liter flow. Adjustments in oxygen prescription were
allowed during this evaluation time peri od lo keep oxygen saturations
greater than 90 %. On the second and third nights Lhe subjects either
received oxygen at their regularly prescribed liter flo w o r they received
oxygen per the 4: I POD at an equivalent setting to their prescribed l.i.ter
0 ow. (See table below). The order for delivery method on the second and
third nig hts will be randomized.

4:1 and variable flow device, wave form characteristics: Calculations made at
18 breaths/minute with l :E ratio of 1:2.

4..1 Tecbno ol!V: 0 xygen usa ~e
bolus
tail
final 0 2 from 0 2 from

flow
rate
(1pm)
0
1/8
1/4
1/2
3/4
1
1 1/2
2
2 1/2
3
3 1/2
4

size

rate

(ml)

(1pm) (1pm)
0
0
1/8
1/8
1/4
1/4
1/2
1/2
3/4
3/4
0.5
0
0.65
0
0.75
0
1
0
1.5
0
1.75
0
2
0

0
0
0
0
0
9
9
12
12
15
15
15

rate

tank/
breath
(ml)
6.94
13.89
27.78
41.67
22.70
25.48
30.33
34.96
47.22
51.85
56.48

canula/
breath
(ml)

6.94
13.89
27.78
41 .67
18.26
21.04
25.89
30.52
42.78
47.41
52.04
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Po lysomnography was performed in accordance with published
guidelines ("Indications and Standards, J 989) and measurements inclu ded
central and occipital EEG, chin and leg EMG, ECG, snoring sounds, air
flow, chest and abdominaJ respiraLory effort, pulse ox imetry, and body
position. The pulse oximelry waveform was monito red for detection of
artifact therefore increasing accuracy of oximetry measurements. A second
micropho ne was placed o n the regulator to record sounds associated with
the pulse tlow of oxygen. Titis additional microphone was used to
determine whether pulses of oxygen were the cause of increased EEG
arousals during sleep. All physio logic signals were d igitized and stored on a
computerized sleep system. (Sandman - NBP) for scoring and analysis.
Sleep stages and arousals were scored according to standard
criteria.(" American Sleep Disorders Assa", 1992). Pulse oximetry
measurements were iligitized and analyzed to yield values for mean and
nadir nocturnal saturatio ns. Additio naJ dala was reported includes, number
of desaluralions and percentage of time spent at a saturatio n ofless than
90%. REM versus Non-REM sleep stage and oxygen saturations will be
compared for nights 2 and 3. Tbe effect of bcx:iy position o n pulse
oximetry was also taken into account and repo rted. All subjects were
observed during sleep for notation of body position and nasal cannula
placement during periods of desaturation.
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Control Group and Study Po pulatio n
Although it is difficulL to blind s ubjects to the delivery device due to
the sensation of the "pulse" of oxygen with the demand flow system, no
spec.ial attempts were made to inform s ubjects of the device that will be
used that specific njght.
Subjects served as their own control. Each subject was studied a
rnirumum of three 11ights with the first nig ht serving as an acclimation as
well as a screening study. On the two nights to follo w, all subjects were
studied one rught as a control night at continuous flow and another night
on the test device.
Mixed gender subjec ts> 18 years of age and diagnosed with

chronic lung disease were recruited. Subjects must have had previously
qualified fo r Nocturnal Oxygen via the HCFA guidelines and must
currently be using between I and 4 L/min c ontinuous oxygen as prescribed
by their physician. A total of 20 evaluable subjects were to be studied.
S ubjects were be rec rujted by Lhe Investigator from area medjcal practices.
Each subject was tested over a 3 to 4 day period. No medications were
contraindicated.
Inclusion and Exclusion Criteria
The fo llowing were used as enrollment criteria and subjects will be
screened by the site research coordinator a nd sleep lab staff.
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6. Subjects must be at least 18 years of age and previously met
requirements for oxygen therapy in accordance with the HCFA
gujdelines.
7. Subjects must currenlly be utilizing nocturnal oxygen therapy at a
prescribed rate between o ne and four liters per minute.
8. Subject must have a previous diagnosis of Chronic Lung Disease,
w hjch must be demonstrated by Pulmonary Functio n representative of
lung disease.
9. Subjects must be wimng to comply with the study protocol including
testing over 3 to 4 nights.

I0. Subjects must exhibit no signs of acute exacerbation of their disease
state
including fever o r purule nt secretions.
6. S ubjects' medjcation regimeo must be previously titrated fo r optimal
treatment affect.
7. S ubjects must be willing to sign informed consent.
Subjects were to be excluded from this study if they did not meet the
specific inclusion criteria, or if:
l. S ubject failed to sign an informed consent
2. S ubject demo nstrated any of the fo llowing any time during the study
period:

•
•
•
•
•
•
•
•
•
•

Unstable or untreated angina
Recent Myocardial infarctio n (within four weeks prior to study)
Acute myocarditis or pericarditis
Aoe urysm of the heart or aorta
Primary pulmonary hypertensio n
Recent systemic or pulm onary e mbo lus (four weeks prior lo study)
A condjtion in whic h S p02 might be invalid (COHb, S ic kle cell)
Untreated o r unstable nocturna l a"thma symptoms.
Previously d iagnosed/cw-rent s igns o f obstruc tive or central apnea
Required oxygen therapy as a life-sustaining measure

Withdraw criteria
Subjects were free to withdraw consent and discontinue participation in the study at any
time without prejudice to furthe r treatment. A subject's participation in t.he study could
have been discontinued at a nytime during the study a t the discre tio n of the investigator.
The fo llowing were used

as criteria for justifiable reasons for the

investigator to remove

a patient from the study:
•

Their treatment o r health would have been compromised by their

continued participation i_n the study.
•

S ubject or site investigator feels that the su~jec t was not willing or able

to continue to participate.
•

The subject wishes to ruscontinue partic ipatio n

Adverse effects of the s tudy were also an indication for the subject to be
taken off of the study. S uc h indications would include but were not Limited
to:
•

Request from the subject to te rmina te the study for any reason

2/26/2002
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•

Any sig ns or symptoms demonstrated by the subject in which the

Investigator felt would place the su~ject in im mediate medical danger.
In the event of the need

Lo

discontinue any subject's participation in the

study, the subject would have been contacted by the investigator and
informed of the reason for discontinuation of study. Any adverse events
will be immediately reported to the Sponsoring research coordinator and
the appropriate infonnation would be provided on the case repott form.
Safety Assessment (Risk/Benefit Analysis)
Although there were no direct medical benefits to the study
subjects, there may be advances in product technology as a resu lt o r this
study, which will ultimate ly benefit patients dependent on LTOT.

A risk to participation in this study was the potential for poor
quality of sleep due to non-acclimation to the PDD and/or sleeping in an
unfamjljar environment. Lf a subject fails to trigger the device their
saturation may dec line. Prior to the sensitivity modifications of this study.
70% of subjects studied triggered the device and sat11rated well. ll was
hypothesized that the study modifications would allow for increased
sensitivity. However, aU subjects were closely monitored in the sleep lab
setting and could be reverted to continuous flow therapy, if required. No
subject e ntered into this study required oxygen therapy as a life-sustaining
measure.
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There are two possible adverse device effects that have been
reported in tbe lilerature. The first is the potential for the inability of Lhe
conserving device to provide oxygen in the volume and delivery method
required Lo oxygena te Lbe palient adequately.(> 88% Sa02 as defined by
the established Medicare guidelines fo r the qualification for need of
supplemental oxygen.) Secondly, there is a risk of the inability of the
patient to trigger the conserving dev ice, resulting in desatumtion,
specifically during REM sleep in COPD patients. Il is anticipated that
either o ne o r both of these e ffects rnight occur during the study.
The safety action that is in place for such anticipated adverse device
effect is to include extensive monitoring. All patients are to be monito red
with full polysomnography, which includes EEG, ECG, EMG, respiratory

rate, oxygen saturatio n, airflow (via pressure transducer), and abdominal
movement fo r effo1t. Prio r to and fo llowing each night of study a no ninvasive blood pressure assessment will be taken. All subjects are a lso
conlinually monitored via d osed circuit video monito ring.
Data collection

AU data for subjects entered into the study was collected digitally.

In addition to the digital recording of the po lysomnograph, specific data
that was reported as primary or secondary outcome measures were
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co llected on a standard case report form (CRF). All CRFs were collected
and used in final analysis of the data.
Efficacy of the study device was determined by two parameters.

1) The mean oxygen saturation of subjects while utilizing the study device
as compared wilh the mean saturations of the same subject during the use
of continuo us flow.
2) the proportion of patients who fail to tolerate the device. A failure to
tolerate the device is defined as a subject who experiences> Len episodes
of desaturation to < 90% for greater Lhan 5 minutes.
This protocol and subject informed consent form are reviewed and
approved by the lnstituliona.J Review Board (lRB) of the testing facility in
complying with the requirements of 2 1 CFR 56 or C PMP/ICH/ 135/95 Part

5.11 before enrollment of subjects. (See Appendix A )

31

Chapter IV
Data CoUectio n

The daLa fro m each subject was accepted fo r analysis wben fo llowing the
acclimation oight, data fo r the control and the measurement nights bad been
completed, subject had agreed to co11tinue in the study, and had not exhibited any
signs o r sympto ms of central or obstructive sleep apnea. All subject data that was
used in the final data collection process was from subjects who were potential
candidates as users of the study product. T his criteria included that tile subject
must have been prescribed continuous oxygen U1erapy, they could no t have a
known need for greater than 4 liters per minute of oxygen under any activitjes of
daily living, and must not have been dependent upon oxygen therapy as a means of
"life suppo rt".
Potential patients who were not enro lled based on screening outcome were
not included in the statistical ana lysis. Data from those patients are reported in
screening data listings only. All patients enrolled .in this study are included in aJJ
data listings of patient characteristics. Only patients that received the test device
are included in summary tables of patient safety and efficacy characteristics.
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Demographic
A total of twenty (20) subjects were studied resulljng in nineteen (19) evaluable
case

report forms. One subject's data was excluded when it was discovered that

her ambulatory oxygen prescription was greater than 4 liters per minute, which
would exclude this subject from candidacy for the cu1Tent product in evaJuation

(H300 HELiOS oxygen portable). The data sample included seven (7) male
patients. The mean age was 69 years old (range 57-77). All subjects had been
previously diagnosed with Chronic Obstructive Lung Disease (COPD) and
prescribed oxygen therapy at a rate of 1-4 I/min of continuous flow oxygen for use
during sleep and no t greater than 4 I/min of oxygen during waking rest or exerc ise.
Mean FEY I for the study subjects was 47.6 of predicted (2 1- 103% range).

Data Results-[ndividual Study Comparison
Oxygen Saturation
Twelve ( 12) of the nineteen ( 19) patients (63%) experienced both mean and nadir
(lowest) oxygen saturaUon of not greater than± 4 oxygen saturation percentage
points of variance during the study night when compared with the same
measurements during the control night of study . The g reatest variance in mean and
nadir oxygen saturatio n was 15 percentage points and 18 percentage points
respectively. Bar graphs of tbe mean saturations as well as the nadir can be seen
below.
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Comparison of Mean Saturation
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Of the 7 subjects who had desaturation greater than 4 percentage points from the
control night, the average time spent in desaturation of less than 88% was 31
minutes (2 1-42.5 minutes range).
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Sleep Quality
Two subjects ( 10%) were reported as having a significant difference in
quality of sleep (S ubject 16 and 18). Both subjects experienced more aro usal and
less total sleep time in REM during the study night when compared to the control
night. The decrease in quality of sleep did no t appear to have a corre latio n to the
trigger of Lhe device but d id seem to correlate with a failure to trigger resulting in
desaturation.
Correlatio n with Pulmonary Function
Data from this small sample set of 19 patie nts showed no correlation
between pulmonary fu nction measures and ability to trigger and/or maintain
oxygen saturation during sleep. Correlations attempted included RV/TLC, FEVl ,

and DJF.
Data Resultc;;-CoJJective Group Data
CoUective d ata analysis was pe1formed on the group as a whole . Here the
mean of the mean oxygen saturations as well as a mean of the nadir sawratio ns
was calculated. A two-tailed t-test was used to compare the data. The mean of
the oxygen saLUratio n of subjects on t he Continuo us Flow device was 96. 18% (Xe
= 98. 18) (SDc = l .64) and the mean of the oxygen saturatio n of the subjects on the
Study Device was 92.42% (Xd = 92.42) (SDd =4.49) This produced a t*= 3.45
with a p value= 0.00 l. A large p value (p > 0.01) would indicate that the two
devices (Continuous flow (Xe) and Study Device (X d)) are not statistically,
significantly different. Therefore, the fact tha t the p value was quite sma ll (p <
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0.00 I) would i11dicate that fo r the group collectively there is a hig h probability that
tbe two forms of oxygen de livery would be statistically, significantly different.
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Chapter V
Discussjon
This study has raised some questions as to the efficacy o f a conserving
device such as HELiOSTM, examined in this s tudy, to JJrovide an equal level of
oxygen saturation as would continuous flow oxygen. HELiOS was very effective
in providing oxygen saturatio n equal to continuous flow in 63% of the subjects
studied but did fail to provide equal saturation in 37% of patients studied. This
study raises several questions to be discussed.
No immediate harm was found Lo have occurred in any patients s tudied,
even those whose oxygen saturation dropped for up to 30 minutes. Therefore, if
in fact, the patient describes significant benefits in qual ity of hle improvements
with the HELiOSTM product and has reported that they are utilizing their oxygen
more hours of the day, sbo uJd these patients not be left on the product? T he data
from rhe NOTT and MRC studies only repo rted that the number of hours per day
that the patients remained on their oxygen was a significant contributor to the
increased longevity of the patients.
S ince the desaturation of all patients seemed to be at1ributed to the inability
to trigger the device and not the volume o f oxygen delivered, it could be assumed
that the actual problem w ith the patients was ventilatio n (depth of respiration) and
not necessarily oxygenation as a primary contributo r. Here desaturation (lack of
appropriate oxygenatio n) was o nly the by-product (symptom) of the actual
problem, which was ventilatio n (depth of respiration). This wou ld indjcate that the
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most effective treatment would be a device that would increase ventilation during
Stages IV and REM sleep.

Study Limitation
This study provided a general basis of information regarding the use of one
conserving device during hours of sleep. A p ri mm-y limiting factor of this study is
the small sample size used to draw conclusion. Large study populations are
typically cost prohibitive in medical device studies. It is the researcher' s belief that
this is the primary reason why additional studies to find more adaptive and
effective medical devices for populations as in this case, the elderly, as well as in
the cac,e of medical devices which are prirmu:ily used by pediatric patients. Study
of a larger sample size would provide much needed data as to d1e efficacy of this
and other devices. This would a lso provide additional data points, al lowin g for
more accurate determinations if there were in fact, con-elations w ith any
pulmonary function values, which could be determined during waki11g hours.
A second limiting faclor in this study was the inability to collect data on the
patients end tidal CO2 (et.CO2) . The continuous monitoring of et.CO2 would
provide additional insight as to the source of these patients' inability to maintain
oxygen saturation during hours of sleep. Information about the patients "depth of
respiration" during sleep could lead to more effective u·eatment modalities which
would provide for ventilatocy support, if in fact dlis did prove to be the source of
the problem for such patients. At the time of this snidy the patient i_nterfaces to be
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used wilh Lhe type of technology needed to provide this parameter was not
available.
Future Study Recommendations
The data from this study does provide some insight into the ability of this
conserving device to be used during hours of sleep, Lhe level of desaturation that
might be expected in some patients, and as expected, the need for additi onal study
in this area. SeveraJ areas of additional study would complement this study.
A more comprehensive study, which provided data as to whether or not

this device did increase the number of hours per day that patients, did use their
oxygen therapy. This study would also provide data that would allow for analysis
as to the significance of the effect of some drop in oxygen saturation at ni.ght, if in
fact, the patient did use their oxygen therapy more hours of the day. Such a study
could be designed similarly to the NOTT 198 1 study. Equally matched study
groups in disease process and severity would need to be established with patient
populations of at least 100 patients per group. The patients would need lo be
studied for a minimum of 24 mo nths with no less than 500 days of data collected.
This was found to be a critical point in the differences in both the MRC and NOTT
studies. Such a study would provide much needed insight into the question as to
whether or not some desaturation of up to 30 minutes during the hours of sleep
could not be off set by increasing the hours of use during the day.
A second study that would provide much needed infonnation for this
patient population would be an evaluation of the true cause and effect of oxygen
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A second study that woul.d provide much needed infonnation for this
patient population wou ld be an evaluation of the true cause and effect of oxygen
desaturation at night for COPD patients. A study. which incorporated the
continuous monitoring of etC02, could provide this information. As previously
mentioned, at the time of this study, the equipment and interface for this
monitoring was not available. However, si nce the time of this study, s uch an
interface has been developed by Oridion Medical Inc. This product, called the
Smart Capnol i ne® 0 2 • when used with the M icrostream® Capnography
technology, al lows for continuous monitoring of etC0 2. The product provides a
unique design interface that monitors during both nasal and oraJ exhalation w hile
providing low flow oxygen therapy. (www.oridio11.co111) Such a study would

provide infonnation that might infonn investigators that the patients lack of
abi lity to maintain oxygenati.o n during s leep is actually a function of their inability
to ventilate appropriately. Therefore, oxygen supplementation is actually treating
the symptom and not the problem. This would open doors for new and better
product development of comfortable non-invasive ventilation devices that would
treat the actual problem. It could be hypothesized that the development of such
products and their effective use would bave even a greater impact on the outcomes
and longevity of COPD patients.

Conclusion
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using an oxygen conserving device did not seem Lo be related Lo the tactile
stimulation o f the device trigger, but did seem to be related to failure to maintain
o ptimum oxygen saturatio n. Considering the potential benefit of this single
interface oxygen delivery device, this oxygen delivery method should be
considered for those patients who can maintain oxygen saturation while using the
device. The use of pulse oximetry to evaluate patients for such techno logy appears
to be an effective measure of the subjects' ability to tolerate tbe device.
Since the release of the HELiOS TM Oxygen System, several additional
devices have been released, which are similarly designed. Although none are
known to have any additional clinical orfina nciaJ benefits, at minimum, there is
additio nal innovation in the area of oxygen therapy deljvery. If the development of

this device has done nothing more; it has placed a sig nificant mark in the
production of oxygen therapy devices. These devices offer care for more than the
o ne million peo ple in the U nited States that must live with the day-to-day
frustratio ns and limitations of Long Term Oxygen T herapy. Long Term Oxygen
Therapy is the o nly effective treatment fo r COPD, a disease with no known cure.
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Appendix A
Title 21 , Part 812
Applicability (Section 812.2)
(b) Abbreviated requirements. The following categories of
investigations are considered to have approved applications for
IDE's, unless FDA has notified a sponsor under §812.20(a) that
approval of an application is required:
(1) An investigation of a device other than a significant risk
device, if the device is not a banned device and the sponsor:
(i) Labels the device in accordance with §812.5;
(ii) Obtains IRB approval of the investigation after presenting the
reviewing IRB with a brief explanation of why the device is not a
significant risk device, and maintains such approval;
(iii) Ensures that each investigator participating in an
investigation of the device obtains from each subject under the
investigator's care, informed consent under Part 50 and
documents it, unless documentation is waived by an IRB under
§56.109(c);
(iv) Complies with the requirements of §812.46 with respect to
monitoring investigations;
(v) Maintains the records required under §812.140(b) (4) and (5)
and makes the reports required under §812.150(b) (1) through (3)
and (5) through (1 O);
(vi) Ensures that participating investigators maintain the records
required by §812.140(a)(3)(i) and make the reports required
under §812.150(a) (1 ), (2), (5) and (7) ; and
(vii) Complies with the prohibitions in §812.7 against promotion and
other practices.
(2) An investigation of a device other than one subject to paragraph
(e) of this section, if the investigation was begun on or before
July 16, 1980, and to be completed, and is completed, on or
before January 19, 1981 .
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Title 21, Part 812
Definitions (Section 812.3)

(m) Significant risk device means an investigational device that:
(1) Is intended as an implant and presents a potential for serious
risk to the health, safety, or welfare of a subject;
(2) Is purported or represented to be for a use in supporting or
sustaining human life and presents a potential for serious risk to
the health, safety, or welfare of a subject;
(3) Is for a use of substantial importance in diagnosing, curing,
mitigating, or treating disease, or otherwise preventing
impairment of human health and presents a potential for serious
risk to the health, safety, or welfare of a subject; or
(4)
Otherwise presents a potential for serious risk to the health,
safety, or welfare of a subject.
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